← All trials
NCT06955260
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Mar 31, 2028
- First posted
- May 2, 2025
- Last posted
- May 2, 2025
- Enrollment
- 410
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Canadian Medical and Surgical Knowledge Translation Research GroupLead sponsor
- Applied Health Research CentreCollaborator
- Canadian Medical and Surgical Knowledge Translation Research GroupSponsor investigator
- Boehringer IngelheimCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.